1
Kenneth W Walker, Frederick W Jacobsen, Taruna Arora: Carrier immunoglobulins and uses thereof. Amgen, Thomas J Wrona, March 31, 2015: US08993727 (6 worldwide citation)

Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacol ...


2
John K Sullivan, Joseph G McGivern, Leslie P Miranda, Hung Q Nguyen, Kenneth W Walker, Shaw Fen Sylvia Hu, Colin V Gegg Jr, Taruna Arora Khare, Beverly S Adler, Francis H Martin: DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression. Amgen, Nisan A Steinberg, October 25, 2011: US08043829 (1 worldwide citation)

Disclosed is a composition of matter comprising a ShK toxin peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive compositio ...


3
Monica Florio, Taruna Arora, Christopher J R Paszty, William G Richards: Bispecific binding agents. AMGEN, Marshall Gerstein & Borun, September 15, 2015: US09133272 (1 worldwide citation)

The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.


4
John K Sullivan, Joseph G McGivern, Leslie P Miranda, Hung Q Nguyen, Kenneth W Walker, Shaw Fen Sylvia Hu, Colin V Gegg Jr, Taruna Arora Khare, Beverly S Adler, Francis H Martin: Methods of using conjugated toxin peptide therapeutic agents. Amgen, Nisan A Steinberg, March 22, 2011: US07910102 (1 worldwide citation)

Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of ...


5
Huiquan Han, Taruna Arora, Qing Chen, Hsieng Sen Lu, Xiaolan Zhou: Antibodies that bind myostatin, compositions and methods. Amgen, Fenwick & West, April 7, 2015: US08999343 (1 worldwide citation)

Myostatin antagonists, including myostatin binding antibodies, are disclosed. Also disclosed are nucleic acids encoding and cells including myostatin antagonists; methods of production; and methods of use.


6
Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen: Beta-klotho binding proteins. NGM Biopharmaceuticals, Jones Day, October 9, 2018: US10093735

The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.


7
Shaw Fen Sylvia Hu, Ian Nevin Foltz, Chadwick Terence King, Yang Li, Taruna Arora: Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof. November 15, 2016: US09493577

The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho ...


8
Shaw Fen Sylvia Hu, Ian Foltz, Chadwick Terence King, Yang Li, Taruna Arora: Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof. March 15, 2016: US09284378

The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho ...


9
John K Sullivan, Joseph G McGivern, Leslie P Miranda, Hung Q Nguyen, Kenneth W Walker, Shaw Fen Sylvia Hu, Colin V Gegg Jr, Taruna Arora Khare, Beverly S Adler, Francis H Martin: Conjugated toxin peptide therapeutic agents. Amgen, Nisan A Steinberg, October 26, 2010: US07820623

Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of ...


10
Kenneth W Walker, Frederick W Jacobsen, Taruna Arora: Carrier immunoglobulins and uses thereof. AMGEN, Angela L Purcell, October 31, 2017: US09803019

Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacol ...